Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.

Autor: Rugo HS; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Umanzor GA; Centro Oncológico Integral with DEMEDICA, San Pedro Sula, Honduras., Barrios FJ; American Cancer Center, Guatemala City, Guatemala., Vasallo RH; Clinical Research RD, Santo Domingo, Dominican Republic., Chivalan MA; CELAN Clínica Médica, Guatemala City, Guatemala., Bejarano S; Excel Medica, San Pedro Sula, Honduras., Ramírez JR; Sanatorio Centro Regional de Sub-Especialidades Médicas (CRESEM), Quetzaltenango, Guatemala., Fein L; Instituto de Oncología de Rosario, Rosario, Argentina., Kowalyszyn RD; Centro de Investigaciones Clínicas, Clínica Viedma, Viedma, Argentina., Kramer ED; Athenex, Inc, Buffalo, NY., Wang H; Athenex, Inc, Buffalo, NY., Kwan MR; Athenex, Inc, Buffalo, NY., Cutler DL; Athenex, Inc, Buffalo, NY.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 01; Vol. 41 (1), pp. 65-74. Date of Electronic Publication: 2022 Jul 20.